1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics of the study population (N = 200)
Variables No.
Median age (range) (yr) 63 (35–92)
Female sex (%) 63 (31.5)
Hypertension (%) 131 (65.5)
Diabetes (%) 60 (30)
Dyslipidemia (%) 102 (51)
Smoker (%) 57 (28.5)
Atrial fibrillation (%) 73 (36.5)
Pre-tPA systolic BP (range) 152 (110–215)
Pre-tPA NIHSS score (range) 19 (3–33)
Median onset to treatment (range) 155 (73–275)
TOAST criteria 
    Large-artery atherosclerosis 52 (26%)
    Cardioembolic 96 (48%)
    Lacunar 0 (0%)
    Undetermined cause 42 (21%)
    Stroke of other etiology 10 (5%)
Location of occlusion 
    Tandem 6 (3%)
    Terminal ICA 53 (26.5%)
    M1 76 (38%)
    Distal MCA 65 (32.5%)
Modified Rankin Scale 0–1 at 3 mo (%) 93 (46.6)
Modified Rankin Scale 5–6 at 3 mo (%) 34 (17)
Note:—TOAST indicates Trial of Org 10172 in Acute Stroke Treatment¹²; BP, blood pressure.